IGC M3
Alternative Names: IGC-M3Latest Information Update: 11 Dec 2023
At a glance
- Originator India Globalization Capital
- Class Antidementias; Small molecules
- Mechanism of Action Amyloid beta-protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Alzheimer's disease
Most Recent Events
- 06 Dec 2023 India Globalization Capital collaborates with Center for research and formation in artificial intelligence to leverage generative AI in clinical development of IGC M3
- 21 Nov 2023 India Globalization Capital plans clinical trial for Alzheimer's disease (unspecified route)
- 21 Nov 2023 India Globalization Capital has patents pending entitled "Method and composition for treating CNS disorders" worldwide